Brookline Capital Management Upgrades Marker Therapeutics (NASDAQ:MRKR) to Strong-Buy

Marker Therapeutics (NASDAQ:MRKR) was upgraded by equities research analysts at Brookline Capital Management to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Separately, LADENBURG THALM/SH SH lifted their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Price Performance

Shares of MRKR stock opened at $1.55 on Monday. Marker Therapeutics has a fifty-two week low of $1.55 and a fifty-two week high of $5.99. The stock’s 50-day simple moving average is $2.92 and its 200-day simple moving average is $3.25.

Insider Buying and Selling at Marker Therapeutics

In other news, Director Steve Elms purchased 11,085 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the completion of the transaction, the director now owns 325,370 shares in the company, valued at $1,041,184. This represents a 3.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Enterprise Associates 16 New acquired 554,250 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was purchased at an average cost of $3.20 per share, with a total value of $1,773,600.00. Following the acquisition, the insider now directly owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. This represents a 51.73 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 17.35% of the company’s stock.

Hedge Funds Weigh In On Marker Therapeutics

An institutional investor recently bought a new position in Marker Therapeutics stock. LPL Financial LLC acquired a new stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 79,730 shares of the company’s stock, valued at approximately $248,000. LPL Financial LLC owned 0.74% of Marker Therapeutics at the end of the most recent quarter. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.